Thymopentin

Thymopentin reproduces the biological activity of the parent 49-amino-acid hormone thymopoietin with just the residues Arg-Lys-Asp-Val-Tyr. It binds thymopoietin receptors on prothymocytes, raising intracellular cAMP and driving differentiation toward mature T-cells; it also increases IL-2 production and restores natural killer activity in immunodeficient states. Unusually, it behaves bidirectionally - it raises depressed T-cell function and can dampen exaggerated responses, which is the rationale for its use in both immunodeficiency and rheumatoid arthritis. Its plasma half-life is measured in seconds, so essentially all of its activity is a triggering effect on cells rather than sustained receptor occupancy.

Targets: Thymopoietin receptor on prothymocytes, CD4/CD8 ratio, IL-2 production, NK cell activity

• · 50 mg three times weekly is the classic Timunox regimen used in primary immunodeficiency and HIV-era studies.
• · Lower daily dosing (1-10 mg) is standard in Chinese practice, where thymopentin is widely used; courses run weeks to months.

Work out your exact syringe units →

• very commonInjection-site pain and erythema— The dominant complaint at 50 mg doses.
• uncommonTransient flushing or warmth— Reported shortly after injection.
• rareHypersensitivity reaction— Rash or urticaria; stop if it occurs.
• rareAutoimmune flare— Theoretical and occasionally reported given the T-cell effects.

• Known hypersensitivity to thymopentin.
• Organ transplant recipients on immunosuppressive therapy.
• Pregnancy - no adequate data.

• conflictcyclosporine-a — Opposing pharmacology; combining defeats the purpose of either.
• redundantthymosin-alpha-1 — Both act on T-cell maturation; running both is duplicative.
• synergyVaccines — Studied as a vaccine adjuvant, particularly for hepatitis B non-responders.

• · CBC with differential and, where available, CD4/CD8 ratio.
• · Watch for injection-site reactions that escalate rather than settle.

Not FDA-approved. Formerly marketed as Timunox in parts of Europe; still in clinical use in China and some Asian markets. Sold elsewhere as a research chemical.

• Timunox (thymopentin) European product information (label)
• Randomised trials of thymopentin in rheumatoid arthritis, 1980s-1990s (trial)
• Thymopentin as a hepatitis B vaccine adjuvant in non-responders (trial)

The clinically important fact about thymopentin is that a 30-second molecule produces effects that take weeks to appear and months to fade. That gap tells you the drug is not working by receptor occupancy - it is a trigger. Binding to thymopoietin receptors on prothymocytes raises intracellular cAMP, and the differentiation programme that follows runs on its own timescale regardless of whether the peptide is still present. This is also why the dosing schedule is three times a week rather than continuous: you are pulsing a switch, not maintaining a level. The second distinctive feature is bidirectionality. In primary immunodeficiency and HIV-era studies thymopentin raised depressed T-cell function; in rheumatoid arthritis, which is the opposite problem, the Lancet trial and the German multicentre study both reported clinical improvement rather than worsening. A drug that helps in both immunodeficiency and autoimmunity is either a genuine rebalancing agent or a drug whose effect sizes are small enough that both signals are noise - and the honest reading of the RA literature, where the effects were modest and inconsistent enough that thymopentin never reached US approval and was withdrawn from several European markets, is that both explanations are live. Note the dose scale as a practical matter: this is the only compound in the class dosed at 50 mg, roughly thirty times the thymosin alpha-1 dose, which reflects how much of it is destroyed before it can act.

The dominant complaint at the registered 50 mg dose is injection-site pain and erythema, and it is genuinely common rather than a footnote - you are putting a large mass of peptide into subcutaneous tissue. People who are used to microgram peptides consistently underestimate this and then reconstitute a 50 mg vial in 1 mL, which makes it worse. The second issue is expectation mismatch: the historical RA trials showed modest, non-durable improvement, and the drug was withdrawn from several European markets precisely because the effect was not reliable enough. Anyone expecting a biologic-grade response is going to be disappointed. Third, hypersensitivity reactions - rash and urticaria - are the reason to stop rather than push through. Finally, product identity is a live risk: RKDVY is trivially easy to synthesise, which cuts both ways, because it also means the mass being sold is cheap and the incentive to verify purity is low.

• Thymopoietin receptor on prothymocytes — Not quantified in modern terms - the binding characterisation predates standard radioligand practice and no Kd is reliably published

  Raises intracellular cAMP and initiates differentiation toward mature T-cell phenotypes. The triggering event, not a sustained occupancy.

• IL-2 production by T-cells — Not applicable - induced output

  Increased IL-2 secretion, which is the proximate driver of the CD4/CD8 normalisation seen in immunodeficient states.

• NK cell cytotoxic function — Not applicable

  Restored in immunodeficient and post-chemotherapy states; not obviously raised above normal in healthy subjects.

• Malaise and colleagues, intravenous thymopentin in active rheumatoid arthritis (double-blind, placebo-controlled, randomised) Randomised controlled trial · n=41 · 7 weeks · 1985

  50 mg three times weekly for three consecutive weeks, followed by four weeks of observation. Significant improvement versus placebo in joint pain, joint swelling and morning stiffness (p<0.05 to p<0.01). Small, short, and the effect faded - but a real randomised result published in the Lancet.

• Lemmel and colleagues, multicentre placebo-controlled study of thymopentin in chronic polyarthritis Multicentre randomised controlled trial · n=119 · 1988

  Immunomodulating therapy with thymopentin in chronic polyarthritis. The larger of the European rheumatoid trials. German-language publication in Deutsche Medizinische Wochenschrift.

• Malaise and colleagues, confirmative study of thymopentin effectiveness in active rheumatoid arthritis Randomised controlled trial · 1985

  Follow-up confirmation study of the Lancet result, published in Survey of Immunologic Research.

Seconds: the injected peptide is already being destroyed. Anything you feel in the first minutes is the injection, not the drug. Days 1-7: nothing established beyond injection-site effects. Weeks 1-2: lymphocyte subset changes appear - this is the first measurable window. Weeks 4-8: in the RA trials clinical improvement in joint pain and morning stiffness became apparent here. Months 2-3: the clinical endpoints in the rheumatoid trials were assessed at this point, and the effect tended to fade after treatment stopped rather than persist. There is no evidence for a durable effect after discontinuation.

The only stack with a genuine rationale and human data behind it is thymopentin plus hepatitis B vaccination in documented non-responders, which is a real if modestly evidenced use. Beyond that, do not run it alongside thymosin alpha-1, thymulin or thymalin - identical claimed endpoint, four times the cost, and thymosin alpha-1 is the only one with modern trial data. Combining with any calcineurin inhibitor is pharmacologically self-defeating. The practical stacking problem nobody mentions is volume: at 50 mg per dose you are injecting 1-2 mL of a concentrated solution three times a week, which does not leave much room for anything else in the same site.

Thymopentin is the honest middle of this class: worse evidence than thymosin alpha-1, far better evidence than Vilon, Crystagen or Thymogen. It is the only compound here with randomised placebo-controlled data in an autoimmune indication, which is unusual for a thymic peptide and the reason its bidirectional framing is taken seriously at all. Against thymosin alpha-1 the practical differences are dose scale (50 mg versus 1.6 mg), half-life (30 seconds versus 2 hours) and regulatory standing (withdrawn in Europe, still used in China, versus approved in over 30 countries). Against thymulin it has actual human trials. If you want the thymic-maturation mechanism with the best evidence, take thymosin alpha-1; if you specifically want the rheumatoid indication, thymopentin is the only member of this class that has ever been tested for it.

$60–$900/month. The range is enormous because the two dosing paradigms differ by fiftyfold. The Chinese hepatitis and adjuvant regimen at 1-10 mg daily consumes 30-300 mg a month and sits at the bottom of this range. The classic Timunox 50 mg three times weekly regimen consumes about 600 mg a month, which at typical research-supplier pricing for 50 mg vials lands near the top. Work out which protocol you are actually running before budgeting.

• ?The 30-second half-life is an in vitro human plasma stability measurement from 1979. No in vivo human terminal half-life, bioavailability, volume of distribution or clearance has ever been published.
• ?The Lemmel 1988 multicentre trial duration was not confirmed from the abstract and is left null rather than estimated.
• ?The thymopoietin receptor on prothymocytes has never been molecularly cloned and no binding affinity is reliably published.
• ?The bidirectional claim - raising depressed immunity and dampening exaggerated immunity - is a reasonable reading of the trial literature but has never been demonstrated within a single controlled study.
• ?Whether the modest RA effects seen in the 1980s trials would survive modern trial standards is unknown, and the market withdrawals suggest scepticism is warranted.
• ?Current Chinese clinical practice uses 1-10 mg daily, which is a completely different exposure from the 50 mg three times weekly Timunox regimen. Which one the outcome data support is not resolved in the accessible literature.

• Short in vitro half-life of thymopoietin32-36 pentapeptide in human plasma Tischio JP, Patrick JE, Weintraub HS, et al., International Journal of Peptide and Protein Research, 1979 · PMID 395119

  The source of the 30-second half-life figure that gets quoted everywhere. Worth knowing it is an in vitro human plasma measurement, not an in vivo terminal half-life.

• Treatment of active rheumatoid arthritis with slow intravenous injections of thymopentin. A double-blind placebo-controlled randomised study Malaise MG, Franchimont P, Bolla K, et al., Lancet, 1985 · PMID 2858708

  The best single piece of human evidence for this compound. 41 patients, three weeks of treatment, significant improvement in pain, swelling and morning stiffness.

• Immunomodulating therapy in chronic polyarthritis with thymopentin. A multicenter placebo-controlled study of 119 patients Lemmel EM, et al., Deutsche Medizinische Wochenschrift, 1988 · PMID 3276492

  The larger European RA trial. German language.

• Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis Malaise M, et al., Survey of Immunologic Research, 1985 · PMID 3898298

  Replication attempt from the same group.

• Myristic acid-modified thymopentin for enhanced plasma stability and immune-modulating activity Tan Y, et al., International Immunopharmacology, 2017 · PMID 28365509

  Illustrates the central engineering problem - the entire modern literature on this molecule is attempts to stop it being destroyed in thirty seconds.

• Synthesis, characterization and biological activities of thymopentin ethyl ester Chi Q, et al., Die Pharmazie, 2008 · PMID 19069236

  Another stabilisation attempt, same motivation.